Table of Contents
Clarithromycin Subject 4003/3212/003 with ERSP Isolates, PPb
All CAP Studies (Pooled): Key Demographics, mITT
Post-Marketing Reports of Symptomatic Liver Injury : 200214202DE (1)
Post-Marketing Reports of Symptomatic Liver Injury : 200214202DE (2)
Post-Marketing Reports of Symptomatic Liver Injury : 200213635DE
Post-Marketing Reports of Symptomatic Liver Injury : 200211855DE
Post-Marketing Reports of Symptomatic Liver Injury : 200211440DE
Telithromycin: Anaerobes – MIC Ranges (µg/mL)
Subject 3014/2004/002 02-HS-598-Live-4x-2
Subject 3014/2004/002 02-HS-598-Live-4x-T
Subject 3014/2004/002 02-HS-598-Live-40x-4
Subject 3014/2004/002 02-HS-598-Live-40x-2
Subject 3014/2004/002 02-HS-598-Live-10x-2
Subject 3000/502/1069 2758470-99-4879-4x001
Subject 3000/502/1069 2758470-99-4879-10x001
Subject 3000/502/1069 2758470-99-4879-20x002
Subject 3000/502/1069 2758470-99-4879-40x001
Subject 3000/502/1069 2758470-99-4879-40x003
Subject 3000/502/1069 2758470-liver-4x-T001
Subject 3000/502/1069 2758470-liver-20x001
Subject 3000/502/1069 2758470-liver-40x001
Telithromycin Subject 3000/605/1091
?QTc vs Telithromycin Plasma Concentration in Phase III Studies
Study 3014: Usual Care
Study 3014: Cardiac AESIs in Subjects at Risk of TdP (1)
Study 3014: Cardiac AESIs in Subjects at Risk of TdP (2)
Subject 200214256DE: Spontaneous Report: Fatal Ventricular Arrhythmia (1)
Subject 200214256DE: Spontaneous Report: Fatal Ventricular Arrhythmia (2)
Subject 200214256DE: Spontaneous Report: Fatal Ventricular Arrhythmia (3)
Subject 200214256DE: Spontaneous Report: Fatal Ventricular Arrhythmia (4)
Subject 200214256DE: Spontaneous Report: Fatal Ventricular Arrhythmia (5)
|